Venkataraman Balasubramanian

Array ( [id] => 12001731 [patent_doc_number] => 20170305885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/649551 [patent_app_country] => US [patent_app_date] => 2017-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 41078 [patent_no_of_claims] => 71 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15649551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12565770 [patent_doc_number] => 10017496 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Uracil derivatives as AXL and c-MET kinase inhibitors [patent_app_type] => utility [patent_app_number] => 15/649526 [patent_app_country] => US [patent_app_date] => 2017-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36791 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15649526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15308955 [patent_doc_number] => 10519168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Synthesis of polycyclic-carbamoylpyridone compounds [patent_app_type] => utility [patent_app_number] => 15/639833 [patent_app_country] => US [patent_app_date] => 2017-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33831 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15639833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15020721 [patent_doc_number] => 20190321365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => Maintenance Therapy for the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 16/312816 [patent_app_country] => US [patent_app_date] => 2017-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16312816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13093221 [patent_doc_number] => 10065941 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-04 [patent_title] => Aminotriazine derivative and pharmaceutical composition comprising the same [patent_app_type] => utility [patent_app_number] => 15/637967 [patent_app_country] => US [patent_app_date] => 2017-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27004 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15637967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14326491 [patent_doc_number] => 10294249 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Boronic acid derivatives and therapeutic uses thereof [patent_app_type] => utility [patent_app_number] => 15/636424 [patent_app_country] => US [patent_app_date] => 2017-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39889 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15636424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717069 [patent_doc_number] => 20170369489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 15/631501 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15631501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929723 [patent_doc_number] => 20190300499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES [patent_app_type] => utility [patent_app_number] => 16/307473 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689499 [patent_doc_number] => 20170355704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE [patent_app_type] => utility [patent_app_number] => 15/630189 [patent_app_country] => US [patent_app_date] => 2017-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85039 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15630189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13193955 [patent_doc_number] => 10111878 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-30 [patent_title] => N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 15/630886 [patent_app_country] => US [patent_app_date] => 2017-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10233 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 254 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15630886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12526836 [patent_doc_number] => 10005788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-26 [patent_title] => Bicyclic fused pyrimidine compounds as TAM inhibitors [patent_app_type] => utility [patent_app_number] => 15/624850 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27391 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 314 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15624850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092514 [patent_doc_number] => 20170349608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'NOVEL CRYSTALLINE FORM OF RIFAXIMIN AND PROCESS FOR ITS PREPARATION' [patent_app_type] => utility [patent_app_number] => 15/614900 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 2988 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15614900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16125851 [patent_doc_number] => 10696665 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => Mutant IDH1 inhibitors [patent_app_type] => utility [patent_app_number] => 16/302797 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17088 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16042889 [patent_doc_number] => 10683303 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-16 [patent_title] => Processes for producing methenamine mandelate [patent_app_type] => utility [patent_app_number] => 16/306719 [patent_app_country] => US [patent_app_date] => 2017-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 1719 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16306719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12562590 [patent_doc_number] => 10016432 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Methanocarba derivatives of pseudoribose that inhibit adenosine kinase [patent_app_type] => utility [patent_app_number] => 15/607379 [patent_app_country] => US [patent_app_date] => 2017-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 17 [patent_no_of_words] => 9030 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15607379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15281709 [patent_doc_number] => 10513509 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-24 [patent_title] => EGFR inhibitor compounds [patent_app_type] => utility [patent_app_number] => 15/603789 [patent_app_country] => US [patent_app_date] => 2017-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22669 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15603789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14227127 [patent_doc_number] => 20190125736 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 16/306506 [patent_app_country] => US [patent_app_date] => 2017-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29363 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16306506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929819 [patent_doc_number] => 20190300547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => TRICYCLIC HETEROCYLIC DERIVATIVES [patent_app_type] => utility [patent_app_number] => 16/302873 [patent_app_country] => US [patent_app_date] => 2017-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 211 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302873 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11949442 [patent_doc_number] => 20170253593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR' [patent_app_type] => utility [patent_app_number] => 15/599006 [patent_app_country] => US [patent_app_date] => 2017-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18910 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15599006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14960551 [patent_doc_number] => 20190307753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS [patent_app_type] => utility [patent_app_number] => 16/301935 [patent_app_country] => US [patent_app_date] => 2017-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16301935 [rel_patent_id] =>[rel_patent_doc_number] =>)